Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A)
Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A)
The aim of the study is to assess the safety & immunogenicity of a pandemic influenza vaccine
 administered at 2 different time points. The Protocol Posting has been updated in order to
 comply with the FDA Amendment Act, Sep 2007.
Inclusion Criteria:

 -  Subjects who the investigator believes that they can and will comply with the
 requirements of the protocol should be enrolled in the study.

 -  A male or female between, and including, 18 and 60 years of age at the time of the
 first vaccination.

 -  Written informed consent obtained from the subject.

 -  Healthy subjects as established by medical history and clinical examination before
 entering into the study.

 -  If the subject is female, she must be of non-childbearing potential; or, if of
 childbearing potential, she must be abstinent or have used adequate contraceptive
 precautions for 30 days prior to first vaccination, have a negative pregnancy test and
 must agree to continue such precautions for two months after completion of the
 vaccination series.

 Exclusion Criteria:

 -  Administration of licensed vaccines within 2 weeks (for inactivated vaccines) or 4
 weeks (for live vaccines) prior to enrolment in this study.

 -  History of vaccination with investigational influenza pandemic vaccine.

 -  History of administration of an experimental/licensed vaccine

 -  Planned administration of a vaccine not foreseen by the study protocol during the
 following periods: from Day 0 up to Day 51; from 2 weeks (for inactivated vaccines) or
 4 weeks (for live vaccines) prior to Month 6 and Month 12; from Month 6 up to Month 6
 + 30 days; from Month 12 up to Month 12 + 30 days.

 -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
 immune-modifying drugs within six months prior to the first administration of the
 candidate vaccines

 -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
 medical history and physical examination

 -  History of hypersensitivity to vaccines.

 -  History of allergic disease or reactions likely to be exacerbated by any component of
 the vaccine.

 -  History of chronic alcohol consumption and/or drug abuse.

 -  Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional
 abnormality, as determined by physical examination or laboratory screening tests.

 -  Serious chronic disease including any medically significant chronic pulmonary,
 cardiovascular, renal, neurological, psychiatric or metabolic disorder, as determined
 by medical history and physical examination.

 -  Acute disease at the time of enrolment.

 -  Administration of immunoglobulins and/or any blood products within the three months
 preceding the first administration of the candidate vaccine or during the study.

 -  Lactating women.

 -  Use of any investigational or non-registered product (drug or vaccine) other than the
 study vaccine(s) within 30 days prior to the first vaccination, or planned use during
 the study period.

 -  Any condition which, in the opinion of the investigator, prevents the subject from
 participation in the study.